Quantum Leap Healthcare Collaborative

Meeting Abstracts

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.

Upcoming Meeting Presentations

Fraser Symmans W, Yau C, Chen Y, et al
Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
In: 
J Clin Oncol 36, 2018 (suppl; abstr 520)
;
 (
), Abstract No. 
520
.
abstract
view original
William Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al
Advances in Precision Medicine in Triple-Negative Breast Cancer: Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL Poster Presentation
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
In: 
J Clin Oncol 36, 2018 (suppl; abstr 520)
;
 (
), Abstract No. 
520
.
abstract
view original
Rosa Isela Gallagher, Julia Dianne Wulfkuhle, Christina Yau, et al
Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
In: 
J Clin Oncol 36, 2018 (suppl; abstr 12103)
;
 (
), Abstract No. 
12103
.
abstract
view original
Wulfkuhle J D, Wolf D M, Yau C, et al
Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients
.
2018 American Society of Cancer Oncology Annual Meeting
June 1-5
2018
In: 
J Clin Oncol 36, 2018 (suppl; abstr 12099)
;
 (
), Abstract No. 
12099
.
abstract
view original
Campbell M, Yau C, Borowsky A, et al.
Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial
.
2017 San Antonio Breast Cancer Symposium
Dec 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl
), Abstract No. 
PD6-08
.
abstract
view original
Yee D, DeMichele A, Isaacs C, et al.
Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
.
2017 San Antonio Breast Cancer Symposium
Dec 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl
), Abstract No. 
GS3-08
.
abstract
view original
Pradhan SM, Carey L, Edmiston S, et al.
P53 mutation and differential response to neoadjuvant chemotherapy in women with locally advanced breast cancer: Results from the I-SPY trial (CALGB 150007/1500012 and ACRIN 6657)
.
2017 American Society of Clinical Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
), Abstract No. 
11099
.
abstract
view original
Partridge SC, Zhang Z, Newitt DC, et al.
ACRIN 6698 trial: Quantitative diffusion-weighted MRI to predict pathologic response in neoadjuvant chemotherapy treatment of breast cancer
.
2017 American Society of Clinical Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
), Abstract No. 
11520
.
abstract
view original
Vidula Neelima, Yau Christina, Hope S. Rugo, et al.
Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics.
.
2017 American Society of Cancer Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
), Abstract No. 
1075
.
abstract
view original
Nanda R, Liu MC, Yau C, et al.
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
.
2017 American Society of Cancer Oncology Annual Meeting
June 2-6
2017
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
), Abstract No. 
506
.
abstract
view original
Li W, Wilmes LJ, Newitt DC, et al.
Diffusion-weighted MRI improves imaging prediction of response in the I-SPY 2 trial
.
2017 San Antonio Breast Cancer Symposium
December 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
), Abstract No. 
P2-09-23
.
abstract
view original
Wolf D, Yau C, Brown-Swigart L, et al.
Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
.
2017 San Antonio Breast Cancer Symposium
December 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
), Abstract No. 
P2-09-08
.
abstract
view original
Yau C, Wolf D, Brown-Swigart L, et al.
Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
.
2017 San Antonio Breast Cancer Symposium
December 5-9
2017
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
), Abstract No. 
PD6-14
.
abstract
view original
Vidula N, Yau C, Wolf DM, et al.
Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes
.
2016 Annual Society of Cancer Oncology Annual Meeting
June 3-7
2016
In: 
J Clin Oncol
2016
;
34
 (
15 Suppl.
), Abstract No. 
1072
.
abstract
view original
DeMichele AM, Moulder S, Buxton M, et al.
Efficacy of T-DM1+ pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
), Abstract No. 
CT042
.
abstract
view original
Buxton M, DeMichele AM, Chia S, et al.
Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
), Abstract No. 
CT106
.
abstract
view original
DeMichele AngelaM, Moulder Stacy, Buxton Meredith, et al.
Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
), Abstract No. 
CT042
.
abstract
view original
Wolf DM, Yau C, Sanil A, et al.
Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
), Abstract No. 
858
.
abstract
view original
Wolf DM, Yau C, Brown-Swigart L, et al.
Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer
.
AACR 107th Annual Meeting 2016
April 16-20
2016
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
), Abstract No. 
859
.
abstract
view original
Li W, Arasu V, Jones EF, et al.
Effect of MR imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes – Results from ACRIN 6657 / I-SPY 1 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
), Abstract No. 
PD3-05
.
abstract
view original
Paoloni M, Lyandres J, Buxton MB, et al.
A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
), Abstract No. 
P2-11-02
.
abstract
view original
Shah M, Jensen R, Yau C, et al.
Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2017
;
77
 (
4 Suppl.
), Abstract No. 
P5-11-18
.
abstract
view original
Yee D, Paoloni M, Van't Veer L, et al.
The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
), Abstract No. 
P6-11-04
.
abstract
view original
Forero A, Yee D, Buxton MB, et al.
Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2017
;
77
 (
4 Suppl.
), Abstract No. 
P6-11-02
.
abstract
view original
Gallagher RI, Yau C, Wolf DM, et al.
Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
), Abstract No. 
P3-05-02
.
abstract
view original
Wolf DM, Yau C, Sanil A, et al.
DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
.
2016 San Antonio Breast Cancer Symposium
December 6-10
2016
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
), Abstract No. 
S2-06
.
abstract
view original
Haddad TC, Shah MD, Symmans WF, et al.
I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically advanced, ER+, HER2- breast cancer and molecular good-prognosis gene signature
.
2015 American Society of Clinical Oncology Annual Meeting
May 29 - June 2
2015
In: 
J Clin Oncol
2015
;
33
 (
15 Suppl.
), Abstract No. 
TPS635
.
abstract
view original
Tripathy D, Chien AJ, Hylton N, et al.
Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial
.
2015 American Society of Clinical Oncology Annual Meeting
May 29 - June 2
2015
In: 
J Clin Oncol
2015
;
33
 (
15 Suppl.
), Abstract No. 
524
.
abstract
view original
Van't Veer L, Esserman L, Sanil A, et al.
DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial
.
2015 American Society of Clinical Oncology Annual Meeting
May 29 - June 2
2015
In: 
J Clin Oncol
2015
;
33
 (
15 Suppl.
), Abstract No. 
521
.
abstract
view original
Vidula N, Yau C, Goga A, et al.
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) expression in primary breast cancer (BC); correlations with clinical characteristics and patient outcomes
.
2015 American Society of Clinical Oncology Annual Meeting
May 29 - June 2
2015
In: 
J Clin Oncol
2015
;
33
 (
15 Suppl.
), Abstract No. 
1090
.
abstract
view original
Albain KS, Leyland-Jones Brian, Symmans Fraser, et al.
The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY2 Trial
.
2015 San Antonio Breast Cancer Symposium
December 8-12
2015
In: 
Cancer Res
2015
;
76
 (
4 Suppl.
), Abstract No. 
P1-14-03
.
abstract
view original
Liu MC, Symmans WF, Yau Christina, et al.
Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial
.
2015 San Antonio Breast Cancer Symposium
December 8-12
2015
In: 
Cancer Res
2015
;
76
 (
4 Suppl.
), Abstract No. 
P3-07-49
.
abstract
view original
Wulfkuhle J, Yau C, Gallagher RI, et al.
Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 8-12
2015
In: 
Cancer Res
2015
;
76
 (
4 Suppl.
), Abstract No. 
P3-07-48
.
abstract
view original
Wulfkuhle JD, Yau C, Wolf DM, et al.
Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
December 8-12
2015
In: 
Cancer Res
2015
;
76
 (
4 Suppl.
), Abstract No. 
P3-07-48
.
abstract
view original
Esserman L, Hylton N, , et al.
The role of MRI in evaluating response to neo-adjuvant chemotherapy treatment: The I-SPY experience
.
9th European Breast Cancer Conference
March 19-21
2014
In: 
Eur J Cancer
2014
;
50
 (
2
), Abstract No. 
.
abstract
view original
Bartelink IH, Prideaux B, Hann B, et al.
Spatial distribution of veliparib measured by matrix-assisted laser desorption ionization mass spectrometry in triple-negative breast cancer tumors
.
2014 American Society of Clinical Oncology Annual Meeting
May 30 - June 3
2014
In: 
J Clin Oncol
2014
;
32
 (
26 Suppl.
), Abstract No. 
161
.
abstract
view original
Park JW, Liu MC, Yee D, et al.
Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
.
AACR Annual Meeting 2014
April 5-9
2014
In: 
Cancer Res
2014
;
74
 (
19 Suppl.
), Abstract No. 
CT227
.
abstract
view original
Glas A, Peeters J, Yau C, et al.
Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
.
26th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics
November 18-21
2014
In: 
Eur J Cancer
2014
;
50
 (
6
), Abstract No. 
532
.
abstract
view original
Bartelink IH, Prideaux B, Hann B, et al.
Spatial distribution of veliparib measured by matrix assisted laser desorption ionization mass spectrometry in triple negative breast cancer tumors
.
2014 American Society of Cancer Oncology Annual Meeting
May 30 - June 3
2014
In: 
Cancer Res
2014
;
75
 (
9 Suppl.
), Abstract No. 
P6-11-02
.
abstract
view original
Fournier MV, Derr A, Margulis A, et al.
Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes
.
2014 San Antonio Breast Cancer Symposium
December 9-13
2014
In: 
Cancer Res
2014
;
75
 (
9 Suppl.
), Abstract No. 
P3-06-19
.
abstract
view original
Wolf MD, Yau C, Sanil A, et al.
Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
.
2014 San Antonio Breast Cancer Symposium
December 9-13
2014
In: 
Cancer Res
2014
;
75
 (
9 Suppl.
), Abstract No. 
P3-06-05
.
abstract
view original
Wolf DM, Yau C, Sanil A, et al.
MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
.
2014 San Antonio Breast Cancer Symposium
December 9-13
2014
In: 
Cancer Res
2014
;
75
 (
9 Suppl.
), Abstract No. 
P3-06-25
.
abstract
view original
Wulfkuhle JD, Yau C, Wolf DM, et al.
Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial
.
2014 San Antonio Breast Cancer Symposium
December 9-13
2014
In: 
Cancer Res
2014
;
75
 (
9 Suppl.
), Abstract No. 
P3-06-15
.
abstract
view original
Yau C, Wolf D, Sanil A, et al.
I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial
.
2014 San Antonio Breast Cancer Symposium
December 9-13
2014
In: 
Cancer Res
2014
;
75
 (
9 Suppl.
), Abstract No. 
P3-06-37
.
abstract
view original
Yau C, Wolf DM, Sanil A, et al.
MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
.
2014 San Antonio Breast Cancer Symposium
December 9-13
2014
In: 
Cancer Res
2014
;
75
 (
9 Suppl.
), Abstract No. 
P3-06-29
.
abstract
view original
DeMichele A, Yee D, Hylton N, et al.
Rationale of the design of the I-SPY trial
.
Markers in Cancer: A joint meeting by ASCO, EORTC and NCI
November 7-9
2013
In: 
Eur J Cancer
2013
;
49
 (
4 Suppl.
), Abstract No. 
SP005
.
abstract
view original
Hylton NM
MR imaging for predicting response to neoadjuvant treatment
.
2013 San Antonio Breast Cancer Symposium
December 10-14
2013
In: 
Cancer Res
2013
;
73
 (
24 Suppl.
), Abstract No. 
ES08-3
.
abstract
view original
Wolf DM, Keck S, Yau C, et al.
Assigning luminal A versus luminal B subtype using the Ki67 index in patients with hormone receptor positive (HR+) breast cancer enrolled in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
.
San Antonio Breast Cancer Symposium
December 10-14
2013
In: 
Cancer Res
2013
;
73
 (
24 Suppl.
), Abstract No. 
P1-02-06
.
abstract
view original
Wolf DM, Daemen A, Yau C, et al.
MammaPrint ultra-high risk score is associated with response to neoadjuvant chemotherapy in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
.
San Antonio Breast Cancer Symposium
Deceber 10-14
2013
In: 
Cancer Res
2013
;
73
 (
24 Suppl.
), Abstract No. 
P1-08-01
.
abstract
view original
Rugo HS, Olopade O, DeMichele A, et al.
Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
.
San Antonio Breast Cancer Symposium
December 10-14
2013
In: 
Cancer Res
2013
;
73
 (
24 Suppl.
), Abstract No. 
S5-02
.
abstract
view original
Wulfkuhle JD, Gallagher RI, Wolf D, et al.
Protein pathway activation mapping of LCM tumor epithelium from I-SPY 1 TRIAL surgical specimens reveals activation of receptor tyrosine kinase drug target signaling networks in the non-responding patient cohort
.
2013 San Antonio Breast Cancer Symposium
December 10-14
2013
In: 
Cancer Res
2014
;
73
 (
24 Suppl.
), Abstract No. 
P6-04-01
.
abstract
view original
Clark AS, Chen J, Kapoor S, et al.
Pretreatment Vitamin D Levels and Response to Neoadjuvant Chemotherapy in the I-SPY 1 TRIAL
.
San Antonio Breast Cancer Symposium
December 4-8
2012
In: 
Cancer Res
2012
;
72
 (
24 Suppl.
), Abstract No. 
P3-06-10
.
abstract
view original
Gluck S, Peeters J, Stork-Sloots L, et al.
Response and long-term outcomes after neo-adjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping using MammaPrint and BluePrint
.
2012 American Society of Clinical Oncology Annual Meeting
June 1-5
2012
In: 
Cancer Res
2012
;
72
 (
24 Suppl.
), Abstract No. 
P3-06-11
.
abstract
view original
Landis MD, Yau C, Neumeister V, et al.
Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival
.
San Antonio Breast Cancer Symposium
Deceumber 4-8
2012
In: 
Cancer Res
2012
;
72
 (
24 Suppl.
), Abstract No. 
P2-10-06
.
abstract
view original
Li X, Arlinghaus LR, Chakravarthy AB, et al.
Quantitative DCE-MRI to predict the response of primary breast cancer to neoadjuvant therapy
.
2012 San Antonio Breast Cancer Symposium
December 4-8
2012
In: 
Cancer Res
2012
;
72
 (
24 Suppl.
), Abstract No. 
P4-01-03
.
abstract
view original
Wolf DM, Yau C, Magbanua M, et al.
Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
.
35th Annual CTRC-AACR San Antonio Breast Cancer Symposium
2012-12-15
2012
In: 
Cancer Res
2012
;
72
 (
24 Suppl.
), Abstract No. 
P2-05-01
.
abstract
view original
Wulfkuhle JD, Yau C, Gallagher RI, et al.
Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2− tumors
.
San Antonio Breast Cancer Symposium
December 4-8
2012
In: 
Cancer Res
2012
;
72
 (
24 Suppl.
), Abstract No. 
P3-04-02
.
abstract
view original
Wulfkuhle JD, Wolf D, Gallagher RI, et al.
Protein pathway activation mapping of the I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with triple negative tumors
.
San Antonio Breast Cancer Symposium
December 4-8
2012
In: 
Cancer Res
2012
;
72
 (
24 Suppl.
), Abstract No. 
P3-04-01
.
abstract
view original
Boudreau A, Yau C, Petrillo L, et al.
Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
.
2011 San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
P5-01-05
.
abstract
view original
Cheang MCU, Prat A, Fan C, et al.
PAM50 HER2−Enriched Subtype Enriches for Tumor Response to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane Containing Regimens in HER2−Positive Breast Cancer
.
2011 San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
S5-2
.
abstract
view original
DeMichele A, Yau C, Zhu J, et al.
Comparison of Community and Central Her2 Assessment on Outcome of Neoadjuvant Chemotherapy in the I-SPY Trial
.
2011 San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
P1-06-11
.
abstract
view original
Gluck S, deSnoo F, Tian S, et al.
Response to Neo-Adjuvant Chemotherapy and Outcomes for I-SPY 1 Patients Stratified by the 70-Gene Prognosis Signature (MammaPrint) and Molecular Subtyping (BluePrint)
.
San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
P1-06-20
.
abstract
view original
Hylton NM, Partridge SC, Rosen M, et al.
ACRIN 6698 MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: A Sub-Study of the I-SPY 2 TRIAL (Investigation of Serial Studies To Predict Your Therapeutic Response with Imaging And moLecular Analysis)
.
San Antonio Breast Cancer Symposium
Deceumber 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
OT2-03-06
.
abstract
view original
Li J, Moore D, Yau C, et al.
RANK Expression in Primary Tumor Tissue at the Time of Diagnosis Correlates with Risk of Subsequent Bone Metastases in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
.
2011 San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
P5-14-0
.
abstract
view original
Mukhtar RA, Lips E, Wesseling J, et al.
Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial
.
San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
P1-06-10
.
abstract
view original
Wolf DM, Yau C, Benz S, et al.
Patient-Specific Integrative Pathway Analysis Using PARADIGM Identifies Key Activities in I-SPY 1 Breast Cancer Patients (CALGB 150007/150012; ACRIN 6657)
.
San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
P1-06-09
.
abstract
view original
Mukhtar RA, Hylton N, Rosen M, et al.
MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial (Abstract PD02-05)
.
San Antonio Breast Cancer Symposium
December 6-10
2011
In: 
Cancer Res
2011
;
71
 (
24 Suppl.
), Abstract No. 
PD02-05
.
abstract
view original
Magbanua MM, Davis SE, Crothers J, et al.
Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy
.
2010 American Society of Oncology Annual Meeting
June 4-8
2010
In: 
J Clin Oncol
2010
;
28
 (
15_suppl
), Abstract No. 
10515
.
abstract
view original
Wulfkuhle JD, Lenburg ME, Pierobon M, et al.
Protein signal pathway mapping of human breast cancer from I-SPY: Correlations with response and genomic subtyping
.
2010
In: 
J Clin Oncol
2010
;
28
 (
15 Suppl.
), Abstract No. 
10512
.
abstract
view original
Alvarado MD, Malik A, Wathen KJ, et al.
Predictors of Local Recurrence in High Risk Patients Undergoing Neoadjuvant Chemotherapy in the I-SPY1 Trial (CALGB 150007/12 ACRIN 6657)
.
2010 San Antonio Breast Cancer Symposium
December 8-12
2010
In: 
Cancer Res
2010
;
70
 (
24 Suppl.
), Abstract No. 
PD06-03
.
abstract
view original
Campbell MJ, Zhu J, Yau C, et al.
Expression of Genes Associated with the Innate Immune System and Response to Neoadjuvant Chemotherapy in Breast Cancer
.
2010 San Antonio Breast Cancer Symposium
December 8-12
2010
In: 
Cancer Res
2010
;
70
 (
24 Suppl.
), Abstract No. 
P5-04-01
.
abstract
view original
Cheang MCU, Parker JS, He X, et al.
Hypoxia ( VEGF-S)Signature and CRYABPredict Response to Neoadjuvant Anthracycline/Taxane Containing Chemotherapy within Triple Negative and Unselected Breast Tumors
.
2010 San Antonio Breast Cancer Symposium
December 8-12
2010
In: 
Cancer Res
2010
;
70
 (
24 Suppl.
), Abstract No. 
PD07-09
.
abstract
view original
Mukhtar RA, Hwang ES, Livasy C, et al.
Response of Invasive Lobular Cancers to Neoadjuvant Therapy
.
2010 San Antonio Breast Cancer Symposium
December 8-12
2010
In: 
Cancer Res
2010
;
70
 (
24 Suppl.
), Abstract No. 
P2-09-11
.
abstract
view original
Perlmutter J, Frank E, LeStage B, et al.
I-SPY 2 Clinical Trial: Advocate Involvement in Protocol, Informed Consent and Patient Support Materials Development
.
2010 San Antonio Breast Cancer Symposium
December 8-12
2010
In: 
Cancer Res
2010
;
70
 (
24 Suppl.
), Abstract No. 
P5-07-02
.
abstract
view original
Perlmutter J, Parker B, Nixon N, et al.
I-SPY 2 Clinical Trial: Telephone Support Provided by Peer Counselors
.
San Antonio Breast Cancer Symposium
December 8-12
2010
In: 
Cancer Res
2010
;
70
 (
24 Suppl.
), Abstract No. 
P2-12-03
.
abstract
view original
Symmans WF, Hatzis C, Valero V, et al.
A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer
.
2010 San Antonio Breast Cancer Symposium‐
December 8-12
2010
In: 
Cancer Res
2010
;
70
 (
24 Suppl.
), Abstract No. 
PD07-03
.
abstract
view original
Esserman LJ, Perou C, Cheang M, et al.
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
.
2009 American Society of Clinical Oncology Annual Meeting
May 29 - June 2
2009
In: 
J Clin Oncol
2009
;
27
 (
18 Suppl
), Abstract No. 
LBA515
.
abstract
view original
DeMichele A, Dunn L, Gimotty P, et al.
Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)
.
2009 American Society of Clinical Oncology Annual Meeting
May 28 - June 2
2009
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
), Abstract No. 
11091
.
abstract
view original
Hylton N, Blume J, Gatsonis C, et al.
MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007
.
2009 American Society of Clinical Oncology Annual Meeting
May 28 - June 2
2009
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
), Abstract No. 
529
.
abstract
view original
Lin C, Moore D, DeMichele A, et al.
Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening
.
2009 American Society of Clinical Oncology Annual Meeting
May 29 - June 2
2009
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
), Abstract No. 
1503
.
abstract
view original
Liotta L, Pierobon M, Wulfkuhle J, et al.
Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes
.
2009 American Society of Clinical Oncology Annual Meeting
August 15
2009
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
), Abstract No. 
11014
.
abstract
view original
van't Veer L, Esserman LJ, Linn S, et al.
Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers
.
2009 American Society of Clinical Oncology Annual Meeting
May 28 - June 2
2009
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
), Abstract No. 
1525
.
abstract
view original
Wulfkuhle J, Pierobon M, Laird J, et al.
Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping
.
2009 American Society of Clinical Oncology Annual Meeting
May 28 - June 2
2009
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
), Abstract No. 
11009
.
abstract
view original
Parker J, Prat A, Cheang M, et al.
Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy
.
2009 San Antonio Breast Cancer Symposium
December 10-13
2009
In: 
Cancer Res
2009
;
69
 (
24 Suppl.
), Abstract No. 
2019
.
abstract
view original
Wolf D, Das D, Lenburg M, et al.
From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657)
.
2009 San Antonio Breast Cancer Symposium
December 10-13
2009
In: 
Cancer Res
2009
;
69
 (
24 Suppl
), Abstract No. 
2042
.
abstract
view original
van't Veer L, Das D, DeMichele A, et al.
Neoadjuvant Response in the Context of a Biologically Defined Low or High Risk Tumor Has a Different Clinical Consequence, the I-SPY Trial (CALGB 150007/150012, ACRIN 6657)
.
2009 San Antonio Breast Cancer Symposium
December 10-13
2009
In: 
Cancer Res
2009
;
69
 (
24 Suppl
), Abstract No. 
2003
.
abstract
view original
Esserman LJ, van't Veer LJ, Perou C, et al.
Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention
.
2008 San Antonio Breast Cancer Symposium
December 10-14
2008
In: 
Cancer Res
2008
;
69
 (
2 Suppl.
), Abstract No. 
6034
.
abstract
view original
Gomez RE, Zakhireh J, Moore D, et al.
Sentinel node biopsy performed in the neoadjuvant setting for breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657)
.
2008 San Antonio Breast Cancer Symposium
December 10-14
2008
In: 
Cancer Res
2009
;
69
 (
2 Suppl.
), Abstract No. 
202
.
abstract
view original
Hylton NM, Blume JD, Bernreuter WK, et al.
Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657
.
2008 San Antonio Breast Cancer Symposium
December 10-14
2008
In: 
Cancer Res
2009
;
69
 (
2 Suppl.
), Abstract No. 
6043
.
abstract
view original
Livasy C, Carey L, DiMichelle A, et al.
Biomarkers associated with pathologic complete response to neoadjuvant chemotherapy in women with locally advanced breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012; ACRIN 6657)
.
San Antonio Breast Cancer Symposium
December 10-14
2008
In: 
Cancer Res
2008
;
69
 (
2 Suppl.
), Abstract No. 
5102
.
abstract
view original
Livasy C, Carey L, DeMichele A, et al.
Influence of anthracycline- and taxane-based neoadjuvant chemotherapy on tumor HER2 protein expression in locally advanced breast cancers: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657)
.
2008 San Antonio Breast Cancer Symposium
December 10-14
2008
In: 
Cancer Res
2009
;
69
 (
2 Suppl.
), Abstract No. 
703
.
abstract
view original
McDaniel SA, Krontiras H, CarpenterJr JT, et al.
Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer
.
June 1-6
2006
In: 
J Clin Oncol
2006
;
24
 (
18 Suppl.
), Abstract No. 
10622
.
abstract
view original
Hylton N
MRI to assess breast cancer response to treatment: experience in the I-SPY/ACRIN trials
.
2013-11-01
In: 
J Nucl Med
2013
;
54
 (
1
), Abstract No. 
.
abstract
view original